Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from SS Innovations International ( (SSII) ).
On May 13, 2026, SS Innovations reported unaudited first-quarter 2026 results showing revenue more than doubled year over year to $11.1 million, driven by a sharp rise in SSi Mantra system sales, instrument and warranty revenue, and a 73.3% increase in new installations to 26. Gross margin improved to 48.0% and net loss narrowed to $3.6 million, while the company ended March with $16.0 million in cash, no long-term debt, a cumulative installed base of 194 systems across 11 countries, and 9,744 cumulative surgeries, underscoring accelerating adoption of its surgical robotics platform.
Operationally, the quarter featured regulatory approvals for SSi Mantra in Sri Lanka and Kenya and for telesurgery use in Indonesia and the Philippines, bolstering SS Innovations’ presence in emerging markets. The company also raised approximately $18.6 million in a March 9, 2026 private placement to fund growth initiatives, reinforcing its bid to solidify its position in India, deepen penetration in underserved regions, and prepare for anticipated entry into the U.S. and European markets, pending regulatory clearances.
Spark’s Take on SSII Stock
According to Spark, TipRanks’ AI Analyst, SSII is a Neutral.
The score is held down primarily by weak financial quality (ongoing losses and worsening cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting these are a strengthened balance sheet and a positive slate of corporate events (regulatory wins, adoption milestones, and fresh capital), while valuation support is limited due to negative earnings and no dividend data.
To see Spark’s full report on SSII stock, click here.
More about SS Innovations International
SS Innovations International, Inc. is a surgical robotics company that develops innovative robotic technologies aimed at making advanced surgery more affordable and accessible globally. Its portfolio centers on the proprietary SSi Mantra surgical robotic system and the complementary SSi Mudra instrument suite, supporting a wide range of procedures, including cardiac and pediatric surgeries, with a particular focus on cost-effective deployment in India and other underserved markets.
Average Trading Volume: 55,205
Technical Sentiment Signal: Sell
Current Market Cap: $823M
Learn more about SSII stock on TipRanks’ Stock Analysis page.